Car­lyle Group in­jects $260M in­to a lead­ing car­dio play­er in Chi­na, grab­bing a seat at the deals ta­ble

The Car­lyle Group is in­vest­ing $260 mil­lion to grab a mi­nor­i­ty stake in Shen­zhen Salu­bris Phar­ma­ceu­ti­cal, a sto­ried gener­ic mak­er that’s in­creas­ing­ly in­vest­ing in new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.